Literature DB >> 26261640

Total ginsenosides synergize with ulinastatin against septic acute lung injury and acute respiratory distress syndrome.

Rongju Sun1, Yana Li2, Wei Chen1, Fei Zhang1, Tanshi Li1.   

Abstract

Total ginsenosides synergize with ulinastatin (UTI) against septic acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). We randomly divided 80 cases of severe sepsis-induced ALI and ARDS into a UTI group and a ginsenosides (GS)+UTI group. Continuous electrocardiac monitoring of pulse, respiratory rate, blood pressure, and heart rate; invasive hemodynamic monitoring; ventilator-assisted breathing and circulation support; and anti-infection as well as UTI treatment were given in the UTI group with GS treatment added for 7 consecutive days in the GS+UTI group. The indicators of pulmonary vascular permeability, pulmonary circulation, blood gases, and hemodynamics as well as APACHE II and ALI scores were detected on days 1, 3, and 7. The ALI score in the GS+UTI group was significantly decreased (P < 0.05) compared with that of the UTI group, and the indicators of pulmonary capillary permeability such as pulmonary vascular permeability index, extravascular lung water index, and oxygenation index, in the GS+UTI group improved significantly more than that of the UTI group. The indicators of hemodynamics and pulmonary circulation such as cardiac index, intrathoracic blood volume index, and central venous pressure improved significantly (P < 0.05), and the APACHE II score in the GS+UTI group was lower than that of the UTI group. GS can effectively collaborate with UTI against ALI and/or ARDS.

Entities:  

Keywords:  ALI; ARDS; Ulinastatin; ginsenoside; sepsis; systemic inflammatory response syndrome

Mesh:

Substances:

Year:  2015        PMID: 26261640      PMCID: PMC4525974     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  20 in total

1.  Ulinastatin attenuates reperfusion injury in the isolated blood-perfused rabbit heart.

Authors:  Z L Cao; Y Okazaki; K Naito; T Ueno; M Natsuaki; T Itoh
Journal:  Ann Thorac Surg       Date:  2000-04       Impact factor: 4.330

2.  Ginsenoside Rg1 reduces toxicity of fine particulate matter on human alveolar epithelial cells: a preliminary observation.

Authors:  Zhi-Guo Zhang; Xu-Yan Niu; Xiao-Juan He; Jun Shu
Journal:  Mol Med Rep       Date:  2013-12-17       Impact factor: 2.952

3.  Effect of Ulinastatin, a human urinary trypsin inhibitor, on the oleic acid-induced acute lung injury in rats via the inhibition of activated leukocytes.

Authors:  Koji Ito; Akio Mizutani; Shinitiro Kira; Masakazu Mori; Hideo Iwasaka; Takayuki Noguchi
Journal:  Injury       Date:  2005-03       Impact factor: 2.586

Review 4.  Urinary trypsin inhibitor as a therapeutic option for endotoxin-related inflammatory disorders.

Authors:  Ken-ichiro Inoue; Hirohisa Takano
Journal:  Expert Opin Investig Drugs       Date:  2010-04       Impact factor: 6.206

5.  Antioxidative, anti-inflammatory, and matrix metalloproteinase inhibitory activities of 20(S)-ginsenoside Rg3 in cultured mammalian cell lines.

Authors:  Yu-Mi Shin; Hyun-Joo Jung; Woo-Yong Choi; Chang-Jin Lim
Journal:  Mol Biol Rep       Date:  2012-10-10       Impact factor: 2.316

6.  Ginsenoside Rg5 ameliorates lung inflammation in mice by inhibiting the binding of LPS to toll-like receptor-4 on macrophages.

Authors:  Tae-Wan Kim; Eun-Ha Joh; Baek Kim; Dong-Hyun Kim
Journal:  Int Immunopharmacol       Date:  2011-11-19       Impact factor: 4.932

7.  Anti-inflammatory effects of ginsenosides Rg5 , Rz1 , and Rk1 : inhibition of TNF-α-induced NF-κB, COX-2, and iNOS transcriptional expression.

Authors:  Sang Myung Lee
Journal:  Phytother Res       Date:  2014-07-21       Impact factor: 5.878

8.  Urinary trypsin inhibitor protects against systemic inflammation induced by lipopolysaccharide.

Authors:  Ken-Ichiro Inoue; Hirohisa Takano; Akinori Shimada; Rie Yanagisawa; Miho Sakurai; Shin Yoshino; Hiroyuki Sato; Toshikazu Yoshikawa
Journal:  Mol Pharmacol       Date:  2004-12-02       Impact factor: 4.436

9.  Acute respiratory distress syndrome: the Berlin Definition.

Authors:  V Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Niall D Ferguson; Ellen Caldwell; Eddy Fan; Luigi Camporota; Arthur S Slutsky
Journal:  JAMA       Date:  2012-06-20       Impact factor: 56.272

Review 10.  Acute lung injury and the acute respiratory distress syndrome in the injured patient.

Authors:  Magdalena Bakowitz; Brandon Bruns; Maureen McCunn
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2012-08-10       Impact factor: 2.953

View more
  11 in total

1.  [Effect of ulinastatin on isoflurane-induced neuronal apoptosis in the hippocampus of rats].

Authors:  Yuanbo Guo; Yan Wang; Dengwen Zhang; Can Cui; Tao Li; Sheng Wang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2019-07-30

2.  Ulinastatin protects the lungs of COPD rats through the HMGB1/TLR4 signaling pathway.

Authors:  Wei Liu; Zhiguang Liu; Weidong Zhang; Shaoxi Cai
Journal:  Oncol Lett       Date:  2018-07-11       Impact factor: 2.967

3.  Effect of Urinary Trypsin Inhibitor (Ulinastatin) Therapy in COVID-19.

Authors:  Ashish Jain; Rajeev Kasliwal; Srishti Suresh Jain; Rohit Jain; Divyansh Gupta; Priyamvada Gupta; Anand Jain; Rohan Tambi; Puneet Panwar; Munesh Meena; Ravi Jain
Journal:  Indian J Crit Care Med       Date:  2022-06

Review 4.  Can natural products modulate cytokine storm in SARS-CoV2 patients?

Authors:  Doha H Abou Baker
Journal:  Biotechnol Rep (Amst)       Date:  2022-06-09

Review 5.  Therapeutic Risk and Benefits of Concomitantly Using Herbal Medicines and Conventional Medicines: From the Perspectives of Evidence Based on Randomized Controlled Trials and Clinical Risk Management.

Authors:  Xiu-Lai Zhang; Meng Chen; Ling-Ling Zhu; Quan Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2017-04-11       Impact factor: 2.629

Review 6.  Effect of Ulinastatin in the Treatment of Postperative Cognitive Dysfunction: Review of Current Literature.

Authors:  Zheng-Tao Lv; Jun-Ming Huang; Jin-Ming Zhang; Jia-Ming Zhang; Jin-Feng Guo; An-Min Chen
Journal:  Biomed Res Int       Date:  2016-08-14       Impact factor: 3.411

7.  Effects of ulinastatin combined with mechanical ventilation on oxygen metabolism, inflammation and stress response and antioxidant capacity of ARDS.

Authors:  Mingxia Ji; Tiejiang Chen; Baiming Wang; Mengyan Chen; Qianqian Ding; Lingchao Chen; Yuejuan Fang; Xiaofang Yu; Yanzhen Chen; Xiaohua Wang; Yiyue He; Yong Jiang
Journal:  Exp Ther Med       Date:  2018-03-30       Impact factor: 2.447

8.  Ulinastatin treatment for acute respiratory distress syndrome in China: a meta-analysis of randomized controlled trials.

Authors:  Xiangyun Zhang; Zhaozhong Zhu; Weijie Jiao; Wei Liu; Fang Liu; Xi Zhu
Journal:  BMC Pulm Med       Date:  2019-11-04       Impact factor: 3.317

9.  Real-world safety of ulinastatin: a post-marketing surveillance of 11,252 patients in China.

Authors:  Jin Li; Meijun Li; Liren Li; Lin Ma; Ailin Cao; Aiping Wen; Wenge Chen; Lingling Li; Yan Liang; Jianxiong Deng
Journal:  BMC Pharmacol Toxicol       Date:  2022-07-16       Impact factor: 2.605

Review 10.  Therapeutic Potential of Ginsenosides as an Adjuvant Treatment for Diabetes.

Authors:  Litao Bai; Jialiang Gao; Fan Wei; Jing Zhao; Danwei Wang; Junping Wei
Journal:  Front Pharmacol       Date:  2018-05-01       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.